The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.

Journal of Virology
Urvi M ParikhJohn W Mellors

Abstract

The K65R mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is selected in vitro by many D-nucleoside analog RT inhibitors (NRTI) but has been rarely detected in treated patients. In recent clinical trials, the K65R mutation has emerged frequently in patients experiencing virologic failure on antiretroviral combinations that do not include 3'-azidothymidine (AZT). The reason for this change is uncertain. To gain insight, we examined trends in the frequency of K65R in a large genotype database, the association of K65R with thymidine analog mutations (TAMs) and other NRTI mutations, and the viral susceptibility profile of HIV-1 with K65R alone and in combination with TAMs. Among >60,000 clinical samples submitted for genotype analysis that contained one or more NRTI resistance mutations, the frequency of K65R increased from 0.4% in 1998 to 3.6% in 2003. Among samples with K65R, a strong negative association was evident with the TAMs M41L, D67N, L210W, T215Y/F, and K219Q/E (P<0.005) but not with other NRTI mutations, including the Q151M complex. This suggested that K65R and TAMs are antagonistic. To test this possibility, we generated recombinant HIV-1 encoding K65R in two different TAM backgrounds:...Continue Reading

References

May 5, 2000·The Biochemical Journal·N Sluis-CremerM A Parniak
Oct 25, 2003·Antimicrobial Agents and Chemotherapy·Katharina WolfBarbara Schmidt
Apr 30, 2004·The New England Journal of Medicine·Roy M GulickUNKNOWN AIDS Clinical Trials Group Study A5095 Team
Dec 21, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Michel Segondy, Brigitte Montes
Mar 8, 2005·Journal of Clinical Microbiology·Jan WeberMiguel E Quiñones-Mateu
May 20, 2005·Journal of Medical Virology·Marc WirdenVincent Calvez
Nov 4, 2005·The Journal of Infectious Diseases·Joel E GallantUNKNOWN ESS30009 Study

❮ Previous
Next ❯

Citations

Aug 7, 2007·AIDS Research and Human Retroviruses·Carmen de MendozaVincent Soriano
Aug 2, 2008·AIDS Research and Human Retroviruses·Elena FerrerDaniel Podzamczer
Nov 27, 2008·AIDS Research and Human Retroviruses·Martin StürmerAnnemarie Berger
Apr 5, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Raph L HamersUNKNOWN PharmAccess African Studies to Evaluate Resistance (PASER)
Jun 6, 2008·AIDS·Robert J MurrayAndrew J Leigh Brown
Aug 1, 2009·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Claudia A HawkinsUNKNOWN APIN Plus/Harvard PEPFAR Team
May 2, 2009·Current Opinion in Infectious Diseases·Ravindra K GuptaDeenan Pillay
Apr 5, 2012·Cold Spring Harbor Perspectives in Medicine·Eric J Arts, Daria J Hazuda
May 28, 2009·Antimicrobial Agents and Chemotherapy·Michel L NtemgwaMark A Wainberg
Jun 27, 2012·Antimicrobial Agents and Chemotherapy·Eugene L AsahchopCécile L Tremblay
Jun 27, 2013·Retrovirology·Eleftherios MichailidisStefan G Sarafianos
Dec 2, 2011·PloS One·Nicole Ngo-Giang-HuongUNKNOWN Program for HIV Prevention and Treatment (PHPT) study group
May 16, 2008·Clinical Pharmacokinetics·Geoffrey J YuenGary E Pakes
Oct 23, 2012·Drugs·Randall Tressler, Catherine Godfrey
Apr 1, 2011·Future Microbiology·Shiro Ibe, Wataru Sugiura
Feb 5, 2013·Journal of the International AIDS Society·Avelin F AghokengMartine Peeters
Mar 7, 2012·Future Virology·Denis R ChoperaZabrina L Brumme
Mar 21, 2007·Applied Microbiology and Biotechnology·Yazan El SafadiRoland Marquet
Apr 23, 2013·Current Opinion in Virology·Kalyan Das, Eddy Arnold
Aug 31, 2011·Antiviral Research·Selwyn J Hurwitz, Raymond F Schinazi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.